AI for Clinical Trials: Patient Recruitment and Monitoring
In phase III clinical trials, budgets start at $200M and timelines span 3–7 years. 30% of failures are due to under-enrollment, and half of sites recruit less than 70% of participants. Each week of delay costs millions. We built AI systems that use NLP, predictive analytics, and synthetic control arms to reduce recruitment time by 40–60% and decrease dropout by 25%. In effect, you get a ready-to-launch cohort in 2–5 minutes instead of weeks of manual screening. Savings on a single phase III study can reach $30 million.
For example, in an Alzheimer's drug trial with 800 participants, AI selected 420 eligible patients in 5 minutes — manually this would have taken 3 weeks. AI screening is over 1000 times faster than manual screening (source). Additionally, AI evaluates sample representativeness and predicts completion rate for each patient using geographic, socioeconomic, and clinical features. This approach enables enrolling first those with high likelihood of completing the study, reducing losses during follow-up.
How AI Patient Screening Works
Each clinical trial contains dozens of inclusion/exclusion criteria in medical English. Our NLP system:
- Parses criteria into a structured representation via clinical concept extraction (SNOMED CT, LOINC, RxNorm).
- Matches against hospital EMR data.
- Ranks patients by probability of successful prescreening.
| Method | Time per 1000 patients | Recall |
|---|---|---|
| Manual screening | 100–200 hours | ~70–80% |
| NLP screening | 2–5 minutes | >92% |
Why AI Protocol Monitoring Is Faster
Traditionally, monitors manually review Case Report Forms. AI automates:
- Safety Signal Detection: real-time analysis of adverse events (AE) coded to MedDRA with disproportionality analysis (PRR, ROR) for early signal detection.
- Protocol Deviation Detection: NLP and rule checking identify deviations from EMR and ePRO data (e.g., patient took a prohibited drug).
- ePRO Quality: model predicts missing data and unrealistic responses based on temporal patterns and response speed.
For adaptive trials, AI supports Bayesian statistics with fast operating characteristic simulations. Manual checks are reduced by 60–70%, and safety signals are detected 2–3 weeks earlier.
Optimizing Site Network
Site Performance Prediction — we predict enrollment rate and data quality for each site based on historical performance, patient population size, and infrastructure. Country Feasibility — AI analyzes regulatory timelines, costs, and approval speed across countries to select the optimal mix for a multinational trial.
What Are Synthetic Control Arms?
Synthetic control arms are built from real-world patient data (RWD) using propensity score matching and machine learning. Regulators FDA and EMA accept this approach for orphan diseases and accelerated pathways.
| Aspect | Traditional Placebo Group | Synthetic Control Arm |
|---|---|---|
| Patient enrollment | 30–50% of all subjects | 0% additional |
| Ethical concerns | Yes (patients receive placebo) | Minimal |
| Cost | High (treatment, monitoring) | Up to 40% budget savings |
| FDA/EMA validation | Fully accepted | Accepted for select cases |
Savings: excluding 30–50% of control group subjects reduces cost and accelerates the study.
How We Predict Dropout
The model analyzes geographic accessibility, socioeconomic factors, compliance history, and visit frequency. This enables selecting patients with high completion probability, reducing dropout rate and speeding up enrollment.
Implementation Process
Implementation proceeds in four stages:
- Protocol Analytics: NLP parsing of criteria and EMR schemas.
- Model Design: architecture selection (BERT, LongFormer), training on clinic data.
- Integration: connection to 3–5 EMR systems via FHIR or HL7v2.
- Testing and Deployment: validation of recall and precision; deployment on-premise or in the cloud.
- Support: staff training, model monitoring in production.
Typical implementation mistakes: incomplete medical term mapping, ignoring regional EMR systems, lack of historical baseline metrics.
What's Included
- Protocol and model documentation.
- Integration with 3–5 EMR systems (FHIR, HL7v2).
- Staff training on using the AI dashboard.
- Technical support during pilot and post-deployment.
Timelines and Cost
For a specific therapeutic area, development takes 3–5 months and typically costs between $200,000 and $500,000. The typical cost of implementing our AI system is $200,000–$500,000 per therapeutic area, with ROI achievable within the first study. We guarantee a detailed estimate within 2 business days. Savings on a typical phase III study can reach $30 million. We bring over 7 years of AI/ML experience and 15+ projects in pharmaceuticals, with certified quality management (ISO 9001).
Contact us for a preliminary evaluation of your protocol. Request a demo of AI screening on your data.
FDA guidance on synthetic control arms for rare diseases confirms the applicability of this approach.